These findings indicate that depleting RFX6 not only suppresses C4‐2R cell proliferation in vitro but also in vivo, highlighting the potential of RFX6 as a valuable biomarker and therapeutic target in enzalutamide‐resistant PCa. Here, RFX6 is linked to posterior cortical atrophy.